BEAM Beam Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BEAM

Price (delayed)

$32.88

Market cap

$3.38B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.5

Enterprise value

$3.34B

?
Relative Growth: Rel. Growth: 82
Relative Strength: Rel. Strength: 78
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 49

Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a ...

Highlights
BEAM's gross profit has surged by 158% year-on-year and by 17% since the previous quarter
Beam Therapeutics's revenue has soared by 158% YoY and by 17% from the previous quarter
BEAM's equity is down by 6% since the previous quarter but it is up by 3.7% year-on-year
The debt has soared by 63% from the previous quarter and by 59% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://beamtx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of BEAM

BEAM stock price

How has the Beam Therapeutics stock price performed over time
Intraday
11.27%
1 week
0.24%
1 month
9.31%
1 year
91.72%
YTD
18.61%
QTD
37.98%

Financial performance

How have Beam Therapeutics's revenue and profit performed over time
Revenue
$164.01M
Gross profit
$164.01M
Operating income
-$371.62M
Net income
-$65.04M
Gross margin
100%
Net margin
-39.7%
BEAM's gross profit has surged by 158% year-on-year and by 17% since the previous quarter
Beam Therapeutics's revenue has soared by 158% YoY and by 17% from the previous quarter
The net margin has soared by 93% YoY and by 31% from the previous quarter
The net income has surged by 83% year-on-year and by 19% since the previous quarter

Price vs fundamentals

How does BEAM's price correlate with its fundamentals

Growth

What is Beam Therapeutics's growth rate over time

Valuation

What is Beam Therapeutics stock price valuation
P/E
N/A
P/B
2.88
P/S
20.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
20.36
The EPS has surged by 89% year-on-year and by 38% since the previous quarter
The price to book (P/B) is 32% lower than the 5-year quarterly average of 3.8 but 23% higher than the last 4 quarters average of 2.1
BEAM's equity is down by 6% since the previous quarter but it is up by 3.7% year-on-year
Beam Therapeutics's revenue has soared by 158% YoY and by 17% from the previous quarter
BEAM's price to sales (P/S) is 100% lower than its 5-year quarterly average of 17078.9 and 31% lower than its last 4 quarters average of 27.0

Efficiency

How efficient is Beam Therapeutics business performance
The return on sales has surged by 93% year-on-year and by 31% since the previous quarter
BEAM's ROIC has soared by 87% YoY and by 25% QoQ
The ROE has soared by 87% YoY and by 19% QoQ
The company's return on assets has surged by 85% YoY and by 19% QoQ

Dividends

What is BEAM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BEAM.

Financial health

How did Beam Therapeutics financials performed over time
BEAM's current ratio has soared by 93% YoY and by 30% QoQ
BEAM's quick ratio has surged by 88% year-on-year and by 27% since the previous quarter
The debt is 78% less than the equity
The company's debt to equity has surged by 83% QoQ and by 57% YoY
The debt has soared by 63% from the previous quarter and by 59% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.